PRELP Protein Inhibits the Formation of the Complement Membrane Attack Complex

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2012 Jan 24

PMID 22267731

Citations 22

Authors

Kaisa E Happonen

Camilla Melin Furst

Tore Saxne

Dick Heinegard

Anna M Blom

Affiliations

Soon will be listed here.

Abstract

PRELP is a 58-kDa proteoglycan found in a variety of extracellular matrices, including cartilage and at several basement membranes. In rheumatoid arthritis (RA), the cartilage tissue is destroyed and fragmented molecules, including PRELP, are released into the synovial fluid where they may interact with components of the complement system. In a previous study, PRELP was found to interact with the complement inhibitor C4b-binding protein, which was suggested to locally down-regulate complement activation in joints during RA. Here we show that PRELP directly inhibits all pathways of complement by binding C9 and thereby prevents the formation of the membrane attack complex (MAC). PRELP does not interfere with the interaction between C9 and already formed C5b-8, but inhibits C9 polymerization thereby preventing formation of the lytic pore. The alternative pathway is moreover inhibited already at the level of C3-convertase formation due to an interaction between PRELP and C3. This suggests that PRELP may down-regulate complement attack at basement membranes and on damaged cartilage and therefore limit pathological complement activation in inflammatory disease such as RA. The net outcome of PRELP-mediated complement inhibition will highly depend on the local concentration of other complement modulating molecules as well as on the local concentration of available complement proteins.

Citing Articles

Comprehensive investigation of proteoglycan gene expression in breast cancer: Discovery of a unique proteoglycan gene signature linked to the malignant phenotype.

Buraschi S, Pascal G, Liberatore F, Iozzo R Proteoglycan Res. 2025; 3(1).

PMID: 40066261 PMC: 11893098. DOI: 10.1002/pgr2.70014.

Aging disrupts blood-brain and blood-spinal cord barrier homeostasis, but does not increase paracellular permeability.

Cummins M, Cresswell E, Bevege R, Smith D Geroscience. 2024; 47(1):263-285.

PMID: 39476323 PMC: 11872845. DOI: 10.1007/s11357-024-01404-9.

PRELP secreted from mural cells protects the function of blood brain barrier through regulation of endothelial cell-cell integrity.

Davaapil H, Hopkins J, Bonnin N, Papadaki V, Leung A, Kosuge H Front Cell Dev Biol. 2023; 11:1147625.

PMID: 37936982 PMC: 10626469. DOI: 10.3389/fcell.2023.1147625.

Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma.

Schafer H, Subbarayan K, Massa C, Vaxevanis C, Mueller A, Seliger B J Transl Med. 2023; 21(1):643.

PMID: 37730606 PMC: 10512569. DOI: 10.1186/s12967-023-04476-x.

Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway.

Dreismann A, Hallam T, Tam L, Nguyen C, Hughes J, Ellis S Immunol Rev. 2022; 313(1):402-419.

PMID: 36369963 PMC: 10099504. DOI: 10.1111/imr.13149.

References

Fraser D, Harris C, Williams A, Mizuno M, Gallagher S, Smith R . Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. J Biol Chem. 2003; 278(49):48921-7. DOI: 10.1074/jbc.M302598200. View

Murphy B, Saunders J, OBryan M, Kirszbaum L, Walker I, dApice A . SP-40,40 is an inhibitor of C5b-6-initiated haemolysis. Int Immunol. 1989; 1(5):551-4. DOI: 10.1093/intimm/1.5.551. View

Bengtsson E, Aspberg A, Heinegard D, Sommarin Y, Spillmann D . The amino-terminal part of PRELP binds to heparin and heparan sulfate. J Biol Chem. 2000; 275(52):40695-702. DOI: 10.1074/jbc.M007917200. View

Sjoberg A, Manderson G, Morgelin M, Day A, Heinegard D, Blom A . Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol. 2008; 46(5):830-9. PMC: 2760063. DOI: 10.1016/j.molimm.2008.09.018. View

Blom A, Kask L, Dahlback B . Structural requirements for the complement regulatory activities of C4BP. J Biol Chem. 2001; 276(29):27136-44. DOI: 10.1074/jbc.M102445200. View

Podack E, KOLB W, MULLER-EBERHARD H . The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J Immunol. 1978; 120(6):1841-8. View

Wang Y, Rollins S, Madri J, Matis L . Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A. 1995; 92(19):8955-9. PMC: 41086. DOI: 10.1073/pnas.92.19.8955. View

Groeneveld T, Oroszlan M, Owens R, Faber-Krol M, Bakker A, Arlaud G . Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J Immunol. 2005; 175(7):4715-23. DOI: 10.4049/jimmunol.175.7.4715. View

Davies A, Simmons D, Hale G, Harrison R, Tighe H, LACHMANN P . CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989; 170(3):637-54. PMC: 2189447. DOI: 10.1084/jem.170.3.637. View

10.

Heinegard D, Larsson T, Sommarin Y, Franzen A, Paulsson M, Hedbom E . Two novel matrix proteins isolated from articular cartilage show wide distributions among connective tissues. J Biol Chem. 1986; 261(29):13866-72. View

11.

Volanakis J, Kaplan M . Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol. 1974; 113(1):9-17. View

12.

Williams A, Mizuno M, Richards P, Holt D, Morgan B . Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum. 2004; 50(9):3035-44. DOI: 10.1002/art.20478. View

13.

Sarma J, Ward P . The complement system. Cell Tissue Res. 2010; 343(1):227-35. PMC: 3097465. DOI: 10.1007/s00441-010-1034-0. View

14.

Malmsten M, Davoudi M, Schmidtchen A . Bacterial killing by heparin-binding peptides from PRELP and thrombospondin. Matrix Biol. 2006; 25(5):294-300. DOI: 10.1016/j.matbio.2006.04.003. View

15.

Sjoberg A, Onnerfjord P, Morgelin M, Heinegard D, Blom A . The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem. 2005; 280(37):32301-8. DOI: 10.1074/jbc.M504828200. View

16.

Grover J, Chen X, Korenberg J, Recklies A, Roughley P . The gene organization, chromosome location, and expression of a 55-kDa matrix protein (PRELP) of human articular cartilage. Genomics. 1996; 38(2):109-17. DOI: 10.1006/geno.1996.0605. View

17.

Nandakumar K, Jansson A, Xu B, Rydell N, Ahooghalandari P, Hellman L . A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis. PLoS One. 2010; 5(10):e13511. PMC: 2958150. DOI: 10.1371/journal.pone.0013511. View

18.

Ferreira V, Cortes C, Pangburn M . Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology. 2010; 215(11):932-40. PMC: 2949450. DOI: 10.1016/j.imbio.2010.02.002. View

19.

LAURELL C, Dahlqvist I, Persson U . The use of thiol-disulphide exchange chromatography for the automated isolation of alpha 1-antitrypsin and other plasma proteins with reactive thiol groups. J Chromatogr. 1983; 278(1):53-61. DOI: 10.1016/s0378-4347(00)84755-6. View

20.

Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E . The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. J Cell Biol. 2009; 187(5):669-83. PMC: 2806584. DOI: 10.1083/jcb.200906014. View